<DOC>
	<DOCNO>NCT01829711</DOCNO>
	<brief_summary>Background : - Moxetumomab pasudotox experimental non-chemotherapy cancer treatment drug . It target CD22 , molecule surface essentially hairy cell leukemia cell . Moxetumomab pasudotox bind CD22 , go cell , release toxin kill cell . In phase I trial activity relapsed/refractory hairy cell leukemia safety profile support clinical study ( http : //ncbi.nlm.nih.gov/pubmed/22355053 ) . This phase III multicenter trial design confirm result .</brief_summary>
	<brief_title>Moxetumomab Pasudotox Advanced Hairy Cell Leukemia</brief_title>
	<detailed_description>Background : - Hairy cell leukemia indolent B-cell leukemia comprise 2 % leukemia , approximately 900 44,000 new case leukemia/year US - Over last two decade , immunotoxin research accumulate support role CD22-targeted therapy treatment HCL . - Moxetumomab pasudotox recombinant immunotoxin contain Fv fragment anti-CD22 monoclonal antibody truncate Pseudomonas exotoxin . - Moxetumomab pasudotox demonstrate high complete response ( CR ) rate patient chemoresistant hairy cell leukemia ( HCL ) show activity pediatric acute lymphoblastic leukemia well . - Modification structure moxetumomab pasudotox greatly improve binding cytotoxicity toward CD22 express malignant cell compare precursor molecule . Preclinical clinical study demonstrate increase bind affinity result improved antitumor activity tolerability - Currently approve agent significant efficacy HCL patient failure standard therapy Design : - This multicenter , single-arm study moxetumomab pasudotox patient relapsed/refractory hairy cell leukemia . - 77 patient enrol receive moxetumomab pasudotox IV day 1 , 3 5 28 day cycle maximum 6 cycle disease progression , unacceptable toxicity occur , subject begin alternate therapy , document CR ( subject assessable minimal residual disease exceed 6 cycle ) . If less equal 2 first 25 patient achieve durable CR , additional patient accrue . - The overall IRB accrual ceiling currently set 80 allow small number patient assessed response .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients must histologically confirm hairy cell leukemia hairy cell leukemia variant .with need therapy Patients must Pseudomonasimmunotoxin naive Patients must least 2 prior purine analog , least 1 course purine analog 1 either rituximub BRAF inhibitor . Men woman age great equal 18 year . ECOG performance status less equal 2 . Patients must adequate organ function EXCLUSION CRITERIA Patients chemotherapy , immunotherapy radiotherapy within 4 week prior enter study . Patients receive investigational agent . Patients know brain metastasis exclude clinical trial Patients clinically significant ophthalmologic finding screen Pregnant breastfeeding female . Positive Hepatitis B core antibody surface antigen unless patient Lamivudine Entecavir Hepatitis B Viral DNA load less 2000 IU/mL . Lymph nod great 4cm prior splenectomy Active second malignancy require treatment minor resection indolent cancer like basal cell squamous skin cancer HIVpositive patient unless take appropriate antiHIV medication CD4 count great 200 . History allogeneic bone marrow transplant . Patients history thromboembolism know congenital hypercoagulable condition . Uncontrolled pulmonary infection , pulmonary edema . Aequate oxygen saturation Radioimmunotherapy within 2 year prior enrollment study . Adequate hematologic function Adequate lung function Patients history thrombotic microangiopathy TTPHUS . Patients QTc interval ( Federica ) elevation &gt; 500 msec base least 2 separate 12lead ECGs Patient high dose estrogen Patients clinical evidence disseminate intravascular coagulation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Moxetumomab Paudotox</keyword>
	<keyword>CAT-8015</keyword>
	<keyword>anti-CD22 recombination immunotoxin</keyword>
	<keyword>Biologic Therapy</keyword>
	<keyword>Recombinant Immunotoxin</keyword>
	<keyword>Monoclonal Antibody</keyword>
	<keyword>Pseudomonas Exotoxin</keyword>
	<keyword>Targeted Therapy</keyword>
</DOC>